SCLXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SCLXW
Scilex Holding Co
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$2.57−0.26 (-9.19%)
Close on Oct 19, 2026
- Market cap
- $17.71M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2019 to 2025
Gross margin
415.8%+324.9 pts over 5 years
Operating margin
-1143.7%−994.1 pts over 5 years
Net margin
-1236.4%−1034.7 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -46.5% | -7.3% | +5.1% | – | |
| Gross profit | -24.9% | +66.5% | +42.5% | – | |
| Free cash flow | -81.0% | – | – | – |
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | 186.8% | |
| Return on assets | – | – | -163.4% | |
| Current ratio | – | 0.17 | 0.08 | |
| Interest coverage | – | -2.7× | -30.2× | |
| Inventory turnover | – | – | -26.4× | |
| Capex to revenue | – | 0.1% | 0.4% | |
| Diluted shares | – | 0M | 0M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Scilex generated $93.79M from operations and spent $17.47M on capital expenditure, dividends and share buybacks. 1% of that went back into the business.
Generated
$93.79M
Used
$17.47M
Capital expenditure$170.00K1%Dividends$17.30M99%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-1236.4%
×Asset turnover0.13×
×Equity multiplier-1.14×
=Return on equity, FY2025186.8%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -1236.4% | 0.13× | -1.14× | 186.8% |
| FY2024 | -128.7% | 0.58× | -0.53× | 39.8% |
| FY2023 | -244.6% | 0.50× | -1.37× | 167.3% |
| FY2022 | -61.4% | 0.46× | -0.88× | 24.9% |
| FY2021 | -282.4% | 0.80× | -0.35× | 79.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$374.05M
- Cash generatingOperating cash flow above zero$3.82M
- Return on assets improvedROA up on the prior year-71.9% → -402.4%
- Earnings backed by cashOperating cash flow above net income$3.82M vs -$374.05M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose0.16 → 0.08
- No dilutionShare count did not rise0M → 0M
- Gross margin improvedGross margin up on the prior year295.81% → 415.83%
- More efficientAsset turnover rose0.56 → 0.33